...
首页> 外文期刊>International Journal of Pharmaceutical Investigation >Formulation and characterization of hydrochlorothiazide solid lipid microparticles based on lipid matrices of Irvingia fat
【24h】

Formulation and characterization of hydrochlorothiazide solid lipid microparticles based on lipid matrices of Irvingia fat

机译:基于欧文氏脂肪脂质基质的氢氯噻嗪固体脂质微粒的制备与表征

获取原文
           

摘要

Introduction:The purpose of this study was to improve the solubilization, bioavailability, and permeability of hydrochlorothiazide (HCTZ) by the formulation and characterization of HCTZ solid lipid microparticles (SLMs) based on fat derived from Irvingia gabonensis var. excelsa (Irvingia wombolu) and Phospholipon?90G (P90G).Materials and Methods:Irvingia fat was extracted from the nut of I. gabonensis var. excelsa using petroleum ether (40-60°C). HCTZ loaded SLM were formulated using hot homogenization method with 5% w/w Irvingia fat/P90G at each of 1:0, 9:1, 4:1, and 3:1 ratios, 1% w/w HCTZ, 1.5% w/w Labrasol? surfactant and distilled water. Subsequently, particle size analysis, pH, syringeability, drug encapsulation efficiency (EE%), yield, freeze-thaw cycle test, drug release, diffusion, and kinetics were evaluated.Results:The SLM dispersions showed a particle size range of 10.15 ± 2.36 to 13.50 ± 6.88 μm and pH of 5.6-6.4 while dispersions containing 3:1 Irvingia fat/P90G passed through most of the needles (18G, 21G, and 22G) after syringeability studies. A single freeze-thaw cycle caused loss of physical integrity. The EE% of the SLMs were ≥80%, with high yield. The highest drug release and diffusion was observed with SLMs prepared with 3:1 Irvingia fat-P90G mixture (HDP3) and Higuchi model best described the kinetics of the HCTZ release by Fickian diffusion.Conclusion:The release and permeability of HCTZ was improved by its incorporation into Irvingia fat and P90G (3:1) as SLMs.
机译:简介:这项研究的目的是通过基于加尔各答(Irvingia gabonensis)变种脂肪的HCTZ固体脂质微粒(SLM)的配制和表征来改善氢氯噻嗪(HCTZ)的溶解度,生物利用度和渗透性。材料和方法:从加蓬I. gabonensis var的坚果中提取Irvingia脂肪。 excelsa使用石油醚(40-60°C)。使用热均质方法以5%w / w Irvingia脂肪/ P90G分别以1:0、9:1、4:1和3:1的比例配制HCTZ负载的SLM,1%w / w HCTZ,1.5%w / w拉布拉索尔?表面活性剂和蒸馏水。随后进行了粒度分析,pH,可注射性,药物包封效率(EE%),收率,冻融循环试验,药物释放,扩散和动力学。结果:SLM分散体的粒径范围为10.15±2.36在进行可注射性研究后,含有3:1 Irvingia脂肪/ P90G的分散体通过大多数针头(18G,21G和22G),达到13.50±6.88μm,pH值为5.6-6.4。单个冻融循环导致物理完整性的损失。 SLM的EE%≥80%,且产率高。用3:1 Irvingia脂肪-P90G混合物(HDP3)制备的SLM观察到最高的药物释放和扩散,Higuchi模型最恰当地描述了Fickian扩散释放HCTZ的动力学。作为SLM掺入Irvingia脂肪和P90G(3:1)中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号